Coronary Drug Project
Cardiovascular Diseases · Coronary Disease · Myocardial Infarction
Enrolment not recorded · Results not recorded
Loading the evidence…
Drug · Peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonist (AGONIST; direct interaction)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Cardiovascular Diseases · Coronary Disease · Myocardial Infarction
Enrolment not recorded · Results not recorded
Cardiovascular Diseases · Coronary Disease · Myocardial Infarction
Enrolment not recorded · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Free fatty acid-overload nephropathy (acute tubular injury)
Low-dose clofibrate pretreatment prevented acute tubular injury without metabolite accumulation via PPARalpha-dependent effects, though PPARalpha-independent toxicity persisted in null mice.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
Model: Protein-overload nephropathy with acute kidney injury induced by bovine serum albumin loading
Clofibrate attenuated kidney damage and hepatic oxidative stress while maintaining serum and hepatic sulfatide levels and hepatic cerebroside sulfotransferase content. Clofibrate alone without protein overload had only minimal effects on these hepatic parameters.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.